T1	Participants 13 61	polyarteritis nodosa and Churg-Strauss syndrome:
T2	Participants 139 198	polyarteritis nodosa (PAN) and Churg-Strauss syndrome (CSS)
T3	Participants 268 280	236 patients
T4	Participants 576 830	71 patients (1981-1983) compared the association of CYC with corticosteroids (CS) and PE to CS and PE, in order to evaluate the efficacy of CYC given as the first-line treatment to control disease activity and subsequent survival of PAN and CSS patients.
T5	Participants 839 870	December 1983 and December 1988
T6	Participants 922 998	at patients without HBV markers and the second at patients with HBV markers.
T7	Participants 1002 1033	78 patients without HBV markers
T8	Participants 1124 1159	33 patients with PAN related to HBV
T9	Participants 1470 1536	56 patients and addressed to severe PAN without HBV markers or CSS
T10	Participants 2404 2422	PAN related to HBV
